PF-07104091 manufacturers
- PF07104091
-
- $131.00
-
2026-07-31
- CAS:2460249-19-6
- Purity: 99.59%
- Supply Ability: 10g
|
| | PF-07104091 Basic information | | Uses |
| Product Name: | PF-07104091 | | Synonyms: | PF-07104091;(1R,3S)-3-[3-[[5-(methoxymethyl)-2-methyl-pyrazole-3-carbonyl]amino]-1H-pyrazol-5-yl]cyclopentyl] N-isopropylcarbamate;PF 7104091;PF7104091;PF-7104091;PF07104091, 10 mM in DMSO;(1R,3S)-3-(5-(3-(methoxymethyl)-1-methyl-1H-pyrazole-5-carboxamido)-1H-pyrazol-3-yl)cyclopentyl isopropylcarbamate;(1R,3S)-3-(3-(3-(methoxymethyl)-1-methyl-1H-pyrazole-5-carboxamido)-1H-pyrazol-5-yl)cyclopentyl isopropylcarbamate | | CAS: | 2460249-19-6 | | MF: | C19H28N6O4 | | MW: | 404.47 | | EINECS: | | | Product Categories: | | | Mol File: | 2460249-19-6.mol |  |
| | PF-07104091 Chemical Properties |
| Boiling point | 567.0±50.0 °C(Predicted) | | density | 1.38±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: Sparingly soluble: 1-10 mg/ml
Ethanol: Sparingly soluble: 1-10 mg/ml | | pka | 12.51±0.46(Predicted) | | InChIKey | MTNBRBDFNSGQKB-DCHPQEBHNA-N | | SMILES | N(C1NN=C([C@H]2CC[C@@H](OC(=O)NC(C)C)C2)C=1)C(C1N(N=C(COC)C=1)C)=O |&1:5,8,r| |
| | PF-07104091 Usage And Synthesis |
| Uses | PF-07104091 can be used to treat advanced solid tumors, especially hormone receptor-positive (HR+)/HER2-negative breast cancer that is resistant to CDK4/6 inhibitors. | | Description | PF-07104091 is an inhibitor of cyclin-dependent kinase 2 (Cdk2; Ki = 1.16 nM).1 It is selective for Cdk2 over glycogen synthase kinase 3β (GSK3β; Ki = 537.81 nM). PF-07104091 decreases proliferation of TOV-21G and OVCAR-3 ovarian and HCT116 colorectal cancer cells (IC50s = 4.8, 0.59, and 0.88 µM, respectively).2 In vivo, PF-07104091 (50 mg/kg per day) reduces tumor volume and weight in an HCT116 mouse xenograft model.WARNING This product is not for human or veterinary use. | | References | [1] JUN TANG . Anilinopyrazole as selective CDK2 inhibitors[J]. Bioorganic & Medicinal Chemistry Letters, 2003, 13 18: Pages 2985-2988. DOI: 10.1016/s0960-894x(03)00630-9
[2] LIU Z, YANG Y, SUN X, et al. Discovery of Novel Antitumor Small-Molecule Agent with Dual Action of CDK2/p-RB and MDM2/p53[J]. Molecules, 2024, 33 1. DOI: 10.3390/molecules29030725 |
| | PF-07104091 Preparation Products And Raw materials |
|